Skip to content
AnalystLens

Exelixis Quarterly Report for Q1 Ended Apr 3, 2026

Filing Date
Filed May 5, 2026
Period End
April 3, 2026
Security
EXEL
One revenue dollarkept$0.34
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Jun ’21Jun ’21
  4. Leadership change8-K · Mar ’25Mar ’25

Summary

Summary of the 10-Q filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported first-quarter 2026 total revenues of $610.8 milliona, up from $555.4 million in the first quarter of 2025, with net product revenues of $555.0 million versus $513.3 million a year earlier.

Net income rose to $210.5 millionb, or $0.79 per diluted share, compared with $159.6 million, or $0.55 per diluted share, in the prior-year quarter. Growth was driven mainly by CABOMETYX, which generated $552.8 million in net product revenues, and by collaboration revenues of $55.8 million, which included a $7.7 million recognition tied to an $8.0 million Takeda commercial milestone. Research and development expenses declined to $199.9 million from $212.2 million, reflecting lower clinical trial costs, while selling, general and administrative expenses rose to $139.6 million, citing marketing for the anticipated zanzalintinib launch.

Capital deployment was significant. Cash, cash equivalents and marketable securities fell to $1.43 billionc from $1.66 billion at December 31, 2025, primarily because of $430.4 million in cash paid for share repurchases. The company had repurchased 13.7 million shares for $590.6 million under its October 2025 program, with about $159.4 million remaining, and in May 2026 its Board authorized an additional $750.0 million repurchase program through December 31, 2027.

Working capital declined to $837.7 milliond. Management stated that existing resources should support operations for at least 12 months.

The filing highlights pipeline and regulatory events, including FDA acceptance of the zanzalintinib NDA for previously treated metastatic colorectal cancer with a PDUFA target date of December 3, 2026, and the expected final OS analysis of STELLAR-303 in mid-2026. It also discusses generic litigation: MSN, Sun (settled in December 2025), and Azurity are consolidated for trial scheduled November 2, 2026, and a Handa 505(b)(2) application for cabozantinib capsules is under challenge.

Key Highlights

  1. Total revenues rose to $610.8 million from $555.4 million, and net product revenues rose to $555.0 million from $513.3 million for the three months ended March 31, 2026.
  2. Net income was $210.5 million, or $0.79 per diluted share, versus $159.6 million, or $0.55 per diluted share, a year earlier.
  3. Research and development expenses decreased to $199.9 million from $212.2 million, primarily due to lower clinical trial costs, while SG&A increased to $139.6 million.
  4. Cash, cash equivalents and marketable securities declined to $1.43 billion from $1.66 billion at December 31, 2025, largely due to $430.4 million in share repurchase payments.
  5. A new $750.0 million share repurchase authorization was approved in May 2026, running through December 31, 2027, following a prior program with $159.4 million remaining.
  6. The FDA accepted the zanzalintinib NDA (with atezolizumab) for previously treated metastatic colorectal cancer under standard review, with a PDUFA target date of December 3, 2026.
  7. Generic challenges continue, with the MSN, Azurity and Handa matters ongoing and a consolidated Delaware trial scheduled for November 2, 2026.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2027, Exelixis kept $0.34.

  1. Revenue$610.8M100.0%
  2. Cost of revenue−$20.0M3.3%
  3. Gross profit$590.9M96.7%
  4. Operating costs−$339.5M55.6%
  5. Operating income$251.3M41.1%
  6. Interest, other & tax−$40.9M6.7%
  7. Net income$210.5M34.5%
Computed from 10-QQ1 FY2027filed May 5, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2027 against Q1 FY2026

Line itemQ1 FY2027Q1 FY2026Change
Revenue$610.81M$555.45M+10.0%
Cost of Revenue$19.95M$19.17M+4.1%
Gross Profit$590.86M$536.27M+10.2%
R&D Expenses$199.92M$212.23M−5.8%
SG&A Expenses$139.60M$137.18M+1.8%
Operating Expenses$359.47M$368.59M−2.5%
Operating Income$251.34M$186.86M+34.5%
Net Income$210.47M$159.62M+31.9%
EPS (Basic)$0.81$0.57+42.1%
EPS (Diluted)$0.79$0.55+43.6%
Shares Outstanding (Basic)258.33M278.80M−7.3%
Shares Outstanding (Diluted)267.32M288.18M−7.2%

Frequently Asked Questions

  1. How did Exelixis perform financially in the first quarter of 2026?

    Total revenues were $610.8 million, up from $555.4 million, and net income was $210.5 million, or $0.79 per diluted share, compared with $159.6 million, or $0.55 per diluted share, in the first quarter of 2025. Income from operations increased to $251.3 million from $186.9 million.

  2. What drove revenue growth?

    Net product revenues increased to $555.0 million from $513.3 million, with CABOMETYX reaching $552.8 million. The filing attributes this to a 7% increase in CABOMETYX units sold and a 1% increase in average net selling price. Collaboration revenues rose to $55.8 million from $42.2 million, driven by higher Ipsen royalties and a Takeda milestone.

  3. How much cash did the company return to shareholders, and what authorizations are in place?

    The company paid $430.4 million for share repurchases in the quarter and repurchased 13.7 million shares in total under its October 2025 program for $590.6 million, leaving about $159.4 million available. In May 2026, the Board authorized up to an additional $750.0 million of repurchases through December 31, 2027.

  4. What are the key pipeline catalysts mentioned in the filing?

    The FDA accepted the zanzalintinib NDA with atezolizumab for previously treated metastatic colorectal cancer with a PDUFA target action date of December 3, 2026. The filing also notes that the final OS analysis of STELLAR-303 is expected in mid-2026 and that top-line results from STELLAR-304 are expected in the second half of 2026.

  5. What legal risks could affect future CABOMETYX revenue?

    Several generic applicants have filed Paragraph IV certifications. The MSN, Azurity and Handa matters are part of ongoing litigation, with the consolidated Delaware trial scheduled for November 2, 2026. Sun was dismissed from the consolidated litigation after a settlement agreement in December 2025. The filing states that approval and launch of follow-on products could significantly decrease U.S. CABOMETYX revenues.